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Recently, there has been growing interest in the association between traumatic brain injury (TBI) and Alzheimer’s Disease (AD).
TBI and AD share many pathologic features including chronic inﬂammation and the accumulation of beta amyloid (Aβ). Data
from both AD and TBI studies suggest that microglia play a central role in Aβ accumulation after TBI. This paper focuses on the
current research on the role of microglia response to Aβ after TBI.
1.Introduction
Recently, there has been growing interest in the association
between traumatic brain injury (TBI) and Alzheimer’s Dis-
ease (AD). The interest grew from several lines of evidence,
including epidemiological studies that demonstrated an
associationofTBIandthedevelopmentofADlaterinlife[1–
7] and autopsy studies that showed acute and chronic AD-
likepathologyinTBIvictims[8,9].Whilemostofthestudies
investigating the association of AD and TBI have focused on
the accumulation and clearance amyloid-β (Aβ)[ 2, 8, 9],
chronic neuroinﬂammation is also a common feature of AD
and TBI, and microglia likely play a central role [10, 11].
In AD, microglia are recruited to newly formed Aβ plaques,
where microglial activation functions as a double-edged
sword, promoting beneﬁcial responses such as Aβ clearance
[12–14] while also eliciting a proinﬂammatory response
[12]. Similar patterns of microglia activation have been
demonstratedbothacutelyandchronicallyafterTBI[15,16].
This paper will explore the current research on the role
of microglia response to Aβ afterTBI.Although there arefew
studies that directly examine microglial reaction to trauma-
inducedAβ,datafromTBIandADexperimentalandhuman
s t u d i e sw i l lb eu s e dt om a k ea na r g u m e n tf o rac e n t r a lr o l e
of microglia in acute and chronic responses to Aβ-mediated
secondary injury after TBI.
2. GeneralMicroglialResponse after TBI
TBI is a disease process in which mechanical injury initiates
cellular and biochemical changes that perpetuate neuronal
injury and death over time, a process known as secondary
injury. Secondary injury begins minutes after injury and can
continueyearsaftertheinitialinsult.Mechanismsimplicated
in secondary injury after TBI include glutamate excitotoxi-
city, blood-brain barrier disruption, secondary hemorrhage,
ischemia, mitochondrial dysfunction, apoptotic and necrotic
cell death, and inﬂammation [17].
As the primary mediators of the brain’s innate immune
response to infection, injury, and disease, microglia react
to injury within minutes. In fact, microglia may represent
the ﬁrst line of defense following injury [18]. Microglial
activation has been demonstrated as early as 72 hours after
injury in human TBI victims and can persist for years after
injury [15, 16, 19, 20]. Experimental models have recapitu-
lated these ﬁndings, with chronic microglial activation being
demonstrated weeks to months after injury [21–24].
Gene-proﬁling studies also strongly implicate early
microglial activation after TBI.
Markers of microglial activation (CD68, MHC-II), stress
responses (p22phox, heme oxygenase 1), and chemokine
expression (CXCL10, CXCL6) have been shown to markedly
increase after experimental models of TBI [25]. Consistent2 International Journal of Alzheimer’s Disease
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Figure 1: Schematic depiction of the beneﬁcial and detrimental
eﬀects of the interaction Aβ -genesis and microglia after traumatic
brain injury.
with early microglial activation after injury, experimental
models have demonstrated rapid increases in expression of
both IL-1β and TNF-α after injury [26, 27]. Much of this
proinﬂammatory cascade may be mediated by Il-1IR, which
is strongly expressed on microglia [27–29]. In addition to
proinﬂammatorycytokines,activatedmicrogliaalsoproduce
other neurotoxic products after injury such as nitric oxide
(NO) and superoxide free radicals that generate reactive
oxygen species (ROS) and reactive nitrogen species (RNS).
Microgliaalsoproduceanumberofneuroprotectivesub-
stances after injury, including anti-inﬂammatory cytokines
(IL-10, IL-1 receptor antagonist (Il-1ra)) and neurotrophic
factors (nerve growth factor, transforming growth factor β
(TGF-β). IL-10, which is elevated acutely after injury in
humans [30], has been shown to have beneﬁcial eﬀects in
experimental models of injury [31]).
These neuroprotective eﬀects may be a result of sup-
pressed microglial production of proinﬂammatory cytokines
[31, 32]. TGF-β also has also been shown to have neuropro-
tective eﬀects after injury, including improved function, de-
creased lesion size, and decreased iNOS production [33, 34].
3.MicroglialResponse toAβ after TBI
Aβ,whichiselevatedacutelyafterTBI,maybeakeymediator
of microglial activation in this setting [35]. In autopsy
studies, Aβ plaques, a hallmark of AD, were present in as
many as 30% of TBI victims (including children) [8, 9]. The
plaques found in TBI patients, which are strikingly similar
to those observed in the early stages of AD, develop rapidly
and can appear within a few hours after injury [9, 36]. TBI-
induced increases in Aβ have been successfully replicated
in animal models of brain trauma [37–40]. Moreover, Aβ
accumulation after TBI has also been shown to be associated
with increases in the enzymes necessary for Aβ-genesis,
including BACE1 protein (β-secretase) and the gamma
secretase complex proteins [41–43].
Microglia may have a dual role in Aβ accumulation and
clearance (Figure 1). Following closed head injury, microglia
have been shown to have increased expression of the gamma
secretase complex proteins, suggesting a role for microglia
in posttraumatic Aβ-genesis [43]. Polymorphisms in the
Aβ-degrading enzyme neprilysin have been shown to aﬀect
rates of Aβ accumulation after TBI [2], suggesting the possi-
bility that changes in microglial neprilysin expression may
be a pathologic mechanism in post-TBI Aβ accumulation
in addition to the known relevance to AD [12]. More-
over, proinﬂammatory cytokines expressed by microglia,
including interferon-γ, interleukin-1β, and tumor necrosis
factor-α, can speciﬁcally stimulate gamma-secretase activity,
concomitant with increased production of Aβ and the intra-
cellular domain of APP (AICD) [44]. Further evidence sug-
gests that increases in the numbers of neurons with elevated
ß-APP concentrations after TBI correlate with increases in
the number of activated microglia expressing IL-1α and that
clusters of dystrophic neurites containing ß-APP are nearly
universally associated with activated microglia expressing IL-
1α [45]. Microglia containing Aβ have also been described
in association with TBI-induced Aβ plaques, suggesting that
phagocytic clearance of plaques may occur [46].
In addition to the temporospatial relationship of
microglial and Aβ after TBI, much of the evidence regarding
the important role of microglia in the modulation of TBI-
induced Aβ is indirect. Most of this indirect evidence is
derived from drug studies, which, while not designed to
demonstrate the important interaction of microglial with
TBI-induced Aβ, have served to demonstrate this vital inter-
action.Manyofthestudiesthathaveindirectlyelucidatedthe
interaction of microglia and Aβ after TBI have focused
on therapeutics targeting postinjury inﬂammation. Minocy-
cline, a compound whose anti-inﬂammatory properties (in-
cluding attenuating microglial activation) have been widely
demonstrated in diﬀerent models of TBI [47, 48], has also
been shown to preclude formation of Aβ through restoration
of the nonamyloidogenic α-secretase pathway of APP pro-
cessing [49]. Interestingly, it has been shown that some other
anti-inﬂammatory compounds that exert neuroprotective
eﬀects in TBI, such as nonsteroidal anti-inﬂammatory drugs,
cholesterol-lowering drugs, and steroid hormones, also
enhance the α-secretase pathway [50–53]. It is unclear from
these studies whether the anti-inﬂammatory and proα-
secretase eﬀects are merely parallel processes, although cer-
tainlydiversionofAPPfromtheproductionofAβ,whichhas
known proinﬂammatory properties including stimulation
of microglial activation, may itself adequately explain
both the anti inﬂammatory and anti amyloidogentic eﬀects.
Additional studies support the observation that suppres-
sion of microglial activation after TBI is also associated with
decreasesininjury-inducedAβ.Apoemimeticpeptides,liver
X-receptor (LXR) agonists, and 3-Hydroxy-3-methylglutaryl
coenzyme A reductase inhibitors (statins) have all been
shown to attenuate microglial activation and mitigate in-
creases in Aβ after TBI [54–56]. It should be noted, however
that none of these earlier studies can deﬁnitively lead one to
conclude whether Aβ i sac a u s e ,p r o d u c t ,o rm e r em a r k e r
of microglial activation and secondary injury after TBI.
However, what can be concluded is that Aβ is an excellent
indicator of microglial activation following TBI.
4. Conclusions andFutureDirections
The link between trauma, microglial activation, and Aβ is
likelytobeextremelycomplex,andworkinthisﬁeldremainsInternational Journal of Alzheimer’s Disease 3
in its infancy. Much of the work is derived from studies
in AD, though the time course and long-term sequelae of
TBI and AD may require separate lines of investigation. One
recurring issue is the role of Aβ in the pathogenesis of
microglial activation after brain injury which parallels the
increasing emphasis on microglial function in the pathogen-
esis of AD.
Prior studies in AD suggest that microglial clearance of
Aβ declines with aging [12]. It is therefore important to
understand how TBI-induced Aβ alters long-term microglial
function and Aβ-clearance. Future work should focus on
whether blocking Aβ-genesis after TBI alters short- and
long-term microglial activation. In addition, therapeutics
targeting microglial-mediated Aβ clearance, such as the new
AD therapeutic bexarotene [57], may hold promise as new
modalities to treat TBI patients.
In this paper, we have attempted to show how a mecha-
nistic understanding of the interaction of Aβ and microglia
afterTBIcouldhavesigniﬁcantimplicationsfortherapeutics,
especially for those at the highest risk for TBI, including
those in the military and those who engage in contact sports.
Furthermore, the advancement of drug discoveries in the
ﬁeld of TBI, such as sex steroids or Apoe mimetics which
alter both microglial function and Aβ metabolism, may have
potentially important roles in TBI as well as other neurode-
generative diseases. Finally, as we advance our mechanistic
understanding of the interaction between microglia and Aβ
after TBI, it is important to understand whether therapeutic
interventions targeting microglia and Aβ will have any eﬀect
on long-term cognitive sequelae in TBI victims.
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